- Poster presentation
- Open Access
Novel restriction factor RNA-associated early-stage anti-viral factor (REAF) inhibits human and simian immunodeficiency viruses
© Marno et al; licensee BioMed Central Ltd. 2013
- Published: 19 September 2013
- Human Immunodeficiency Virus
- Nucleic Acid
- Viral Replication
- Potent Inhibitor
- Surveillance System
The discovery of novel anti-viral restriction factors illuminates unknown aspects of innate sensing and immunity. We identified RNA-associated Early-stage Anti-viral Factor (REAF) using a whole genome siRNA screen for restriction factors to Human Immunodeficiency Virus (HIV) that act in the early phase of viral replication.
We observed more than 50 fold rescue of HIV-1 infection, using a focus forming unit (FFU) assay, following knockdown of REAF by specific siRNA. Quantitative PCR was used to measure the effect of REAF knockdown on two steps in the replication cycle - production of reverse transcripts and integration of viral cDNA. Both steps were strongly enhanced. Conversely, when REAF is over expressed in target cells fewer reverse transcripts are produced. Human REAF can also inhibit HIV-2 and simian immunodeficiency virus (SIV) infection. REAF associates with viral nucleic acid and may act to prevent reverse transcription.
This report firmly places REAF alongside APOBECs and the recently described SAMHD1 as a potent inhibitor of HIV replication acting early in the replication cycle, just after cell entry. We propose that REAF is part of an anti-viral surveillance system destroying incoming retroviruses. This novel mechanism could apply to invasion of cells by any intracellular pathogen.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.